Multiple sclerosis Press Release

Title Picture
11/29/2018 - 17:42
Novartis announces EU approval of Gilenya for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe
Novartis's picture
Novartis
11/19/2018 - 02:58
New immunotherapy improves MS symptoms
QueenslandUniv's picture
QueenslandUniv
11/14/2018 - 12:18
Lyfebulb Partners with Celgene to Inspire Patient-Driven Innovation in the Management of Multiple Sclerosis
Celgene's picture
Celgene
10/18/2018 - 12:21
Yale-led team finds missing-in-action MS genes
YaleUniversity's picture
YaleUniversity
10/11/2018 - 19:51
Breadth of data at ECTRIMS underpins Novartis' relentless commitment to decoding the science of multiple sclerosis (MS) and decreasing the patient burden
Novartis's picture
Novartis
10/10/2018 - 19:33
Survey Results Presented at ECTRIMS Reveal People with Multiple Sclerosis Want More Information on Brain Atrophy
Celgene's picture
Celgene
10/10/2018 - 17:35
Sanofi Presents 8-Year Data on Lemtrada (Alemtuzumab)
Genzyme's picture
Genzyme
10/10/2018 - 16:57
Sanofi presents new data on Aubagio (teriflunomide)
Genzyme's picture
Genzyme
10/10/2018 - 15:52
Teva Presents 25-year Safety Data from Longest Continuous Trial of COPAXONE (glatiramer acetate injection) for the Treatment of Relapsing Forms of Multiple Sclerosis
Teva Pharmaceutical's picture
Teva Pharmaceutical
10/10/2018 - 14:59
Drug Shows Promise for Progressive Multiple Sclerosis
Northwestern University's picture
Northwestern Un...
10/10/2018 - 09:35
New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018
Celgene's picture
Celgene
10/09/2018 - 20:14
Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya over Copaxone in patients with relapsing remitting multiple sclerosis
Novartis's picture
Novartis
10/09/2018 - 16:14
OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression over Five Years in Relapsing and Primary Progressive Multiple Sclerosis
Genentech's picture
Genentech
10/08/2018 - 18:48
Reversing Paralysis: Stem cell therapy aims to repair spinal cords afflicted by rare disorder
UTSouthwestern's picture
UTSouthwestern
10/08/2018 - 18:01
Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
Novartis's picture
Novartis
10/07/2018 - 20:17
More Than 30 Data Presentations from Sanofi Genzymes Multiple Sclerosis Franchise to Be Featured at the 34th ECTRIMS Congress
Genzyme's picture
Genzyme
10/07/2018 - 19:47
Teva to Present New Data at 34th European Committee for Treatment and Research in Multiple Sclerosis Congress in Berlin
Teva Pharmaceutical's picture
Teva Pharmaceutical
10/02/2018 - 13:26
Roche to present five-year OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive multiple sclerosis (MS) at ECTRIMS
Rocheusa's picture
Rocheusa
10/01/2018 - 13:43
Genentech to Present Five-Year OCREVUS (Ocrelizumab) Efficacy and Safety Data in Relapsing and Primary Progressive Multiple Sclerosis at ECTRIMS
Genentech's picture
Genentech
09/20/2018 - 23:35
Novartis receives positive CHMP opinion for Gilenya for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe
Novartis's picture
Novartis
09/20/2018 - 00:30
New test detects tell-tale danger signs in spinal fluid
YaleUniversity's picture
YaleUniversity
09/12/2018 - 15:26
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya in children and adolescents with MS
Novartis's picture
Novartis
09/12/2018 - 00:53
Major trial of statins to treat multiple sclerosis begins
UniversityCollegeLondon's picture
UniversityColle...
08/30/2018 - 13:09
Study finds multiple sclerosis drug slows brain shrinkage
NIH's picture
NIH
08/29/2018 - 13:11
Phase 2 Clinical Trial of Oral Ibudilast Demonstrates Slowing of Brain Atrophy in Progressive MS
National MS Society's picture
National MS Society
07/30/2018 - 06:56
Thank You Challenge Walk MS National Sponsor
National MS Society's picture
National MS Society
07/16/2018 - 18:06
Genetic marker paves way to prevent serious side effect of multiple sclerosis treatment
BYU's picture
BYU
06/19/2018 - 18:51
Scientists unravel DNA code behind rare neurologic disease
UTSouthwestern's picture
UTSouthwestern
06/14/2018 - 10:08
Roche announces new OCREVUS (ocrelizumab) data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive multiple sclerosis
Rocheusa's picture
Rocheusa
06/13/2018 - 10:06
Genentech Announces New Ocrevus (Ocrelizumab) Data on Long-Term Disability Benefits in Primary Progressive Multiple Sclerosis and Initiation of two Global Studies in Progressive MS
Genentech's picture
Genentech
06/05/2018 - 00:25
UT Southwestern experts help paralyzed college student walk again
UTSouthwestern's picture
UTSouthwestern
05/30/2018 - 01:50
MS Progression Linked to Grey Matter Atrophy
Celgene's picture
Celgene
05/29/2018 - 07:54
Remington College Partners with National Multiple Sclerosis Society for Nationwide Volunteer Effort
wwellons's picture
wwellons
05/11/2018 - 13:28
FDA expands approval of Gilenya to treat multiple sclerosis in pediatric patients
FDA's picture
FDA
05/09/2018 - 19:34
Spinal Fluid Could be Used to Predict the Progression of Multiple Sclerosis, Study Finds
University of Birmingham's picture
University of B...
04/26/2018 - 17:40
Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE (glatiramer acetate injection) 40 mg/mL
Teva Pharmaceutical's picture
Teva Pharmaceutical
04/24/2018 - 06:33
New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting
Celgene's picture
Celgene
04/23/2018 - 17:04
Guidelines Released by AAN to Help Inform Treatment Choices for Multiple Sclerosis
National MS Society's picture
National MS Society
04/23/2018 - 07:17
Relapsing MS Patients Who Switched to Aubagio (teriflunomide) Reported Increased Treatment Satisfaction in Two Clinical Studies
Genzyme's picture
Genzyme
04/23/2018 - 05:24
Treatment Effects Maintained over Seven Years in Patients with Relapsing Remitting Multiple Sclerosis Who Received Lemtrada (alemtuzumab) in Clinical Trials
Genzyme's picture
Genzyme
04/21/2018 - 20:37
New OCREVUS (Ocrelizumab) Data at AAN Demonstrate Significant Reductions in Disease Activity and Disability Progression in Relapsing Multiple Sclerosis
Genentech's picture
Genentech
04/16/2018 - 01:52
Roche to present new data at AAN highlighting extensive research for OCREVUS and expanding neuroscience pipeline
Rocheusa's picture
Rocheusa
04/14/2018 - 23:14
Genentech to Present New Data at AAN Highlighting Extensive Research for Ocrevus and Expanding Neuroscience Pipeline
Genentech's picture
Genentech
04/10/2018 - 04:39
Mylan to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acetate Product through an Investment and Partnership with Israeli Company Mapi Pharma
Mylan's picture
Mylan
04/04/2018 - 02:19
NICE says initial 'no' to ocrelizumab for relapsing MS
MS Society's picture
MS Society
03/29/2018 - 00:37
MS nurses speak out about harm caused by the benefits system
Ekklesia's picture
Ekklesia
03/26/2018 - 21:10
San Diego County Credit Union returns as title sponsor of 2018 Walk MS
San Diego County Credit Union's picture
San Diego Count...
03/23/2018 - 12:34
MS stem cell treatment stabilises disease and reduced disability, trial shows
SheffieldUniv's picture
SheffieldUniv
03/21/2018 - 18:52
Siponimod can slow disability in early secondary progressive MS
MS Society's picture
MS Society
03/20/2018 - 08:06
The Search Continues for More Multiple Sclerosis Treatment Options
Celgene's picture
Celgene
03/18/2018 - 16:21
HSCT works for people with relapsing MS who don't respond to existing DMTs
MS Society's picture
MS Society
03/12/2018 - 10:53
Greensboro Practice Recognized for MS Care
Cone Health's picture
Cone Health
02/27/2018 - 14:55
Celgene Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis
Celgene's picture
Celgene
02/16/2018 - 05:25
Regional brain shrinkage in MS predicts disability
UniversityCollegeLondon's picture
UniversityColle...
02/12/2018 - 23:29
Momenta Pharmaceuticals Announces FDA Approval and Launch of Glatopa (glatiramer acetate injection) 40 mg/mL
Momenta's picture
Momenta
02/05/2018 - 16:31
MS researchers identify new switch for brain repair
MS Society's picture
MS Society
01/12/2018 - 10:23
Ocrelizumab licensed for people with early primary progressive MS in the UK
MS Society's picture
MS Society
01/12/2018 - 00:59
Roches OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis
Rocheusa's picture
Rocheusa
01/10/2018 - 12:14
Relapse Rates: A Benchmark for Measuring MS Treatment Efficacy
Celgene's picture
Celgene
01/09/2018 - 14:17
Effects of estrogen treatment combat multiple sclerosis in mice
UCLA's picture
UCLA